What are the most common side effects of Epoetin Alfa-Epbx?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for Epoetin Alfa-Epbx. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is Epoetin Alfa-Epbx the same as Retacrit?

Retacrit is a brand name for Epoetin Alfa-Epbx. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

Epoetin Alfa-Epbx

Q: What is Epoetin Alfa-Epbx used for?

Epoetin Alfa-Epbx (brand name Retacrit) is a Other indicated for and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac.

Q: How does Epoetin Alfa-Epbx work?

Epoetin Alfa-Epbx works through the following mechanism: 12.1 Mechanism of Action Epoetin alfa products stimulate erythropoiesis by the same mechanism as endogenous erythropoietin..

Other

Brand names: Retacrit

Intravenous, Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Epoetin alfa products stimulate erythropoiesis by the same mechanism as endogenous erythropoietin.

Indications

and upon initiation

there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective

noncardiac

nonvascular surgery ( 1.4 ). Limitations of Use RETACRIT has not been shown to improve quality of life

fatigue

or patient well-being ( 1.5 ). RETACRIT is not indicated for use: • In patients with cancer receiving hormonal agents

Contraindications

• infants
• pregnant women
• and lactating women [see Warnings and Precautions (5.9)
• Use in Specific Populations (8.1
• 8.2

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit ( 5
• Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer ( 5
• Seizures: Epoetin alfa products increase the risk for seizures in patients with CKD ( 5
• Serious Allergic Reactions: Discontinue RETACRIT and manage reactions ( 5

Known Side Effects

7 documented side effects by frequency

Shortness of Breath

1-10%

Nausea

1-10%

Vomiting

1-10%

Itching

1-10%

Diarrhea

0.1-1%

Low Blood Pressure

0.1-1%

Weakness

0.1-1%

Community Discussions

No community discussions found for Epoetin Alfa-Epbx yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → Epoetin Alfa-Epbx openFDA label JSON → Epoetin Alfa-Epbx FAERS adverse-event reports → Epoetin Alfa-Epbx ClinicalTrials.gov → completed Phase 2+ trials of Epoetin Alfa-Epbx

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous, Subcutaneous